CL2008002542A1 - Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. - Google Patents
Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.Info
- Publication number
- CL2008002542A1 CL2008002542A1 CL2008002542A CL2008002542A CL2008002542A1 CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1 CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- pharmaceutical composition
- amyloidosis
- amyloid
- dementia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPUESTOS REPRESENTADOSPOR LA FÓRMULA (I-1), O SUS SALES FARMACOLÓGICAMENTE ACEPTABLES, DONDE X1 Y HET SON COMO SE DEFINE EN LAS REIVINDICACIONES. COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHOS COMPUESTOS O SUS SALES FARMACOLÓGICAMENTEACEPTABLES, EN FORMA DE UN INGREDIENTEACTIVO. USO DE DICHA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR UNA ENFERMEDAD CAUSADA POR AMILOIDE-B, TAL COMO ENFERMEDADDE ALZHEIMER, DEMENCIA, SÍNDROME DE DOWN O AMILOIDOSIS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007225045 | 2007-08-31 | ||
JP2008020009 | 2008-01-31 | ||
JP2008123057 | 2008-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008002542A1 true CL2008002542A1 (es) | 2009-01-02 |
Family
ID=40387302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008002542A CL2008002542A1 (es) | 2007-08-31 | 2008-08-28 | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9453000B2 (es) |
EP (2) | EP2559693B1 (es) |
JP (1) | JP5433418B2 (es) |
KR (1) | KR20100055456A (es) |
CN (1) | CN101815713B (es) |
AR (1) | AR068121A1 (es) |
AU (1) | AU2008292390B2 (es) |
BR (1) | BRPI0815773A2 (es) |
CA (1) | CA2694401C (es) |
CL (1) | CL2008002542A1 (es) |
ES (1) | ES2529648T3 (es) |
IL (1) | IL203778A (es) |
MX (1) | MX2010002098A (es) |
MY (1) | MY150507A (es) |
NZ (1) | NZ583515A (es) |
PE (1) | PE20090674A1 (es) |
TW (1) | TW200916469A (es) |
WO (1) | WO2009028588A1 (es) |
ZA (1) | ZA201000474B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US8129530B2 (en) * | 2007-08-31 | 2012-03-06 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
MY150507A (en) | 2007-08-31 | 2014-01-30 | Eisai R&D Man Co Ltd | Polycyclic compound |
EP2324009A1 (en) * | 2008-08-27 | 2011-05-25 | Eisai R&D Management Co., Ltd. | Process for preparing certain cinnamide compounds |
TR201807944T4 (tr) | 2008-11-19 | 2018-06-21 | Forum Pharmaceuticals Inc | (R)-7-kloro-N-(kinüklidin-3-il)benzo[b]tiyofen-2-karboksamit ve bunun farmasötik olarak kabul edilebilir tuzları ile şizofreninin negatif belirtilerinin tedavisi. |
TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
MX2011006782A (es) * | 2009-02-26 | 2011-07-20 | Eisai R&D Man Co Ltd | Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma. |
AU2010218714A1 (en) | 2009-02-26 | 2011-09-08 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
JP2012051805A (ja) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | テトラヒドロトリアゾロピリジン誘導体の製造方法 |
JP2012121809A (ja) * | 2009-02-26 | 2012-06-28 | Eisai R & D Management Co Ltd | 多環式化合物の製造法およびその中間体 |
EP2429518A1 (en) * | 2009-05-11 | 2012-03-21 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
EA201190256A1 (ru) * | 2009-05-11 | 2012-08-30 | Зе Реджентс Оф Зе Юниверсити Оф Калифорния | Способ снижения уровня убиквитинилированных белков |
WO2011012319A1 (en) * | 2009-07-31 | 2011-02-03 | Sandoz Ag | Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method |
NZ601150A (en) * | 2010-01-15 | 2014-06-27 | Janssen Pharmaceuticals Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
NO3029039T3 (es) | 2010-05-17 | 2018-01-20 | ||
ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
EP3666272A1 (en) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit |
MX355164B (es) | 2012-05-16 | 2018-04-06 | Janssen Pharmaceuticals Inc | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
CN104918938B (zh) | 2012-12-20 | 2017-08-15 | 詹森药业有限公司 | 新颖的作为γ分泌酶调节剂的三环3,4‑二氢‑2H‑吡啶并[1,2‑a]吡嗪‑1,6‑二酮衍生物 |
WO2014111457A1 (en) | 2013-01-17 | 2014-07-24 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
US10372396B2 (en) * | 2013-02-21 | 2019-08-06 | Lenovo ( Singapore) Pte. Ltd. | Discovery and connection to wireless displays |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
EA033423B1 (ru) | 2015-02-03 | 2019-10-31 | Pfizer | Циклопропанбензофуранилпиридопиразиндионы |
WO2018222922A1 (en) * | 2017-06-02 | 2018-12-06 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
MX2020008082A (es) * | 2018-02-05 | 2020-09-24 | Univ Strasbourg | Compuestos y composiciones para el tratamiento del dolor. |
US20220096451A1 (en) * | 2019-02-07 | 2022-03-31 | Alsatech, Inc. | Polyvalent derivatives of emoxypine |
WO2024127030A1 (en) * | 2022-12-15 | 2024-06-20 | Sitryx Therapeutics Limited | Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1101156A (en) | 1965-09-22 | 1968-01-31 | Hickson & Welch Ltd | Triazole derivatives and their use as optical whitening agents |
FR2314731A1 (fr) | 1975-06-19 | 1977-01-14 | Nelson Res & Dev | Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients |
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4508718A (en) | 1984-01-16 | 1985-04-02 | Warner-Lambert Company | Cardiotonic and antihypertensive oxadiazinone compounds |
ES2061432T3 (es) | 1985-10-09 | 1994-12-16 | Shell Int Research | Nuevas amidas de acido acrilico. |
US4783463A (en) | 1985-10-23 | 1988-11-08 | Rorer Pharmaceutical Corporation | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure |
DE3541716A1 (de) | 1985-11-26 | 1987-05-27 | Celamerck Gmbh & Co Kg | Neue acrylsaeureamide |
FI91754C (fi) | 1986-12-02 | 1994-08-10 | Tanabe Seiyaku Co | Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi |
FI902321A0 (fi) | 1989-05-19 | 1990-05-09 | Eisai Co Ltd | Butensyraderivat. |
JPH03206042A (ja) * | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
DK0468054T3 (da) | 1990-02-08 | 1997-06-16 | Eisai Co Ltd | Benzensulfonamidderivat |
AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
JPH10510512A (ja) | 1994-10-04 | 1998-10-13 | 藤沢薬品工業株式会社 | 尿素誘導体とacat阻害剤としての用途 |
JPH08283219A (ja) | 1995-04-07 | 1996-10-29 | Eisai Co Ltd | アラルキルアミノアルキルアミド誘導体 |
CZ251896A3 (en) | 1995-09-12 | 1997-04-16 | Hoffmann Ka Roche Ag F | Cephalosporin derivatives |
WO1997014417A1 (en) | 1995-10-19 | 1997-04-24 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
YU49898A (sh) | 1996-05-10 | 2000-03-21 | Icos Corporation | Hemijska jedinjenja |
CA2260860A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
US5672612A (en) | 1996-09-09 | 1997-09-30 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
JP2001508767A (ja) | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | 5―ht拮抗作用を有するインドール―ウレア誘導体 |
US6407129B1 (en) | 1997-03-31 | 2002-06-18 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and their use |
JP3108997B2 (ja) | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
WO1998046605A1 (en) | 1997-04-16 | 1998-10-22 | Abbott Laboratories | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors |
TW379224B (en) | 1997-12-02 | 2000-01-11 | Fujisawa Pharmaceutical Co | Urea derivatives |
CA2317008C (en) | 1997-12-31 | 2009-01-20 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US6048678A (en) * | 1998-12-28 | 2000-04-11 | Eastman Kodak Company | Protective overcoat coating compositions |
US6235728B1 (en) | 1999-02-19 | 2001-05-22 | Bristol-Myers Squibb Company | Water-soluble prodrugs of azole compounds |
IL144781A0 (en) | 1999-02-26 | 2002-06-30 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
US7053087B1 (en) | 1999-03-04 | 2006-05-30 | Cardiome Pharma Corp. | Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics |
EP1264820A4 (en) | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
US20010051642A1 (en) | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
JP2003531194A (ja) | 2000-04-24 | 2003-10-21 | メルク フロスト カナダ アンド カンパニー | プロスタグランジンe阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物 |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
SI1349839T1 (es) | 2000-12-04 | 2005-08-31 | Hoffmann La Roche | |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
WO2003022273A1 (en) | 2001-09-13 | 2003-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
MXPA04002404A (es) | 2001-09-14 | 2004-05-31 | Novo Nordisk As | Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. |
EP1447401A1 (en) | 2001-11-22 | 2004-08-18 | Ono Pharmaceutical Co., Ltd. | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
NZ533603A (en) | 2001-12-20 | 2007-02-23 | Bristol Myers Squibb Co | Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome |
JP2003206280A (ja) | 2001-12-28 | 2003-07-22 | Takeda Chem Ind Ltd | ビアリール化合物およびその用途 |
EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
WO2003074497A1 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
DE60335635D1 (de) | 2002-05-22 | 2011-02-17 | Amgen Inc | Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen |
DK1511710T3 (en) | 2002-05-31 | 2014-02-24 | Proteotech Inc | RELATIONSHIPS, PREPARATIONS AND METHODS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHES, SUCH AS ALZHEIMER'S DISEASE, TYPE 2-DIABETES AND PARKINSON'S DISEASE |
WO2004002478A1 (en) | 2002-06-27 | 2004-01-08 | Elan Pharmaceuticals, Inc. | Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere |
NZ537603A (en) | 2002-07-12 | 2006-09-29 | Sanofi Aventis Deutschland | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
US6900354B2 (en) | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
US20040192743A1 (en) | 2003-02-12 | 2004-09-30 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
TW200510362A (en) | 2003-04-01 | 2005-03-16 | Plus Chemicals Bv | Amorphous simvastatin calcium and methods for the preparation thereof |
MXPA05012281A (es) * | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
CN1787822A (zh) * | 2003-05-14 | 2006-06-14 | 托里派因斯疗法公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
OA13347A (en) | 2003-12-22 | 2007-04-13 | Pfizer | Triazole derivatives as vasopressin antagonists. |
NZ548208A (en) | 2004-02-12 | 2010-09-30 | Transtech Pharma Inc | Substituted azole derivatives, compositions, and methods of use |
US7598264B2 (en) | 2004-03-09 | 2009-10-06 | Merck & Co., Inc. | HIV integrase inhibitors |
TWI335816B (en) | 2004-05-26 | 2011-01-11 | Eisai R&D Man Co Ltd | Cinnamide compound |
US20080261952A1 (en) | 2004-08-16 | 2008-10-23 | Jason Bloxham | Aryl Urea Derivatives for Treating Obesity |
AU2005297966B2 (en) | 2004-10-26 | 2010-12-23 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
WO2007034282A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
JPWO2007058304A1 (ja) | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
WO2007058305A1 (ja) | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | シンナミド誘導体の製造方法 |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
RU2381225C1 (ru) | 2005-11-24 | 2010-02-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производное циннамида типа морфолина |
US20070117839A1 (en) | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
CA2643796A1 (en) * | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivatives |
AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
JP2010518080A (ja) * | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
US20080207900A1 (en) | 2007-02-28 | 2008-08-28 | Teiji Kimura | Two cyclic oxomorphorin derivatives |
WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
WO2008137139A1 (en) | 2007-05-07 | 2008-11-13 | Schering Corporation | Gamma secretase modulators |
WO2008138753A1 (en) | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
EP2185522A1 (en) | 2007-08-06 | 2010-05-19 | Schering Corporation | Gamma secretase modulators |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
MY150507A (en) | 2007-08-31 | 2014-01-30 | Eisai R&D Man Co Ltd | Polycyclic compound |
CA2707712A1 (en) | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
US20110086850A1 (en) * | 2008-04-11 | 2011-04-14 | Board Of Regents, The University Of Texas System | Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy |
EP2324009A1 (en) | 2008-08-27 | 2011-05-25 | Eisai R&D Management Co., Ltd. | Process for preparing certain cinnamide compounds |
CA2759126C (en) | 2009-02-26 | 2017-08-22 | Boehringer Ingelheim International Gmbh | Compounds as bradykinin b1 antagonists |
JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
MX2011006782A (es) | 2009-02-26 | 2011-07-20 | Eisai R&D Man Co Ltd | Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma. |
US8357716B2 (en) | 2009-02-26 | 2013-01-22 | Glaxo Group Limited | Pyrazole derivatives used as CCR4 receptor antagonists |
US9067344B2 (en) | 2009-02-27 | 2015-06-30 | Hoya Corporation | Mold and method for producing plastic lens |
CA2778517A1 (en) | 2009-07-15 | 2011-01-20 | Janssen Pharmaceuticals, Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
US8381014B2 (en) * | 2010-05-06 | 2013-02-19 | International Business Machines Corporation | Node controller first failure error management for a distributed system |
-
2008
- 2008-08-28 MY MYPI20100422 patent/MY150507A/en unknown
- 2008-08-28 CN CN200880104785XA patent/CN101815713B/zh not_active Expired - Fee Related
- 2008-08-28 JP JP2009530168A patent/JP5433418B2/ja not_active Expired - Fee Related
- 2008-08-28 NZ NZ583515A patent/NZ583515A/en not_active IP Right Cessation
- 2008-08-28 PE PE2008001455A patent/PE20090674A1/es not_active Application Discontinuation
- 2008-08-28 EP EP12191398.2A patent/EP2559693B1/en active Active
- 2008-08-28 WO PCT/JP2008/065365 patent/WO2009028588A1/ja active Application Filing
- 2008-08-28 ES ES12191398.2T patent/ES2529648T3/es active Active
- 2008-08-28 CL CL2008002542A patent/CL2008002542A1/es unknown
- 2008-08-28 AU AU2008292390A patent/AU2008292390B2/en not_active Ceased
- 2008-08-28 US US12/671,873 patent/US9453000B2/en not_active Expired - Fee Related
- 2008-08-28 EP EP08828870.9A patent/EP2181992B8/en active Active
- 2008-08-28 MX MX2010002098A patent/MX2010002098A/es active IP Right Grant
- 2008-08-28 CA CA2694401A patent/CA2694401C/en not_active Expired - Fee Related
- 2008-08-28 AR ARP080103739A patent/AR068121A1/es unknown
- 2008-08-28 BR BRPI0815773A patent/BRPI0815773A2/pt not_active IP Right Cessation
- 2008-08-28 TW TW097132893A patent/TW200916469A/zh unknown
- 2008-08-28 KR KR1020107005314A patent/KR20100055456A/ko active IP Right Grant
-
2010
- 2010-01-21 ZA ZA2010/00474A patent/ZA201000474B/en unknown
- 2010-02-08 IL IL203778A patent/IL203778A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US9453000B2 (en) | 2016-09-27 |
EP2181992B8 (en) | 2013-06-26 |
EP2181992B1 (en) | 2013-05-01 |
AU2008292390B2 (en) | 2013-04-04 |
JPWO2009028588A1 (ja) | 2010-12-02 |
BRPI0815773A2 (pt) | 2019-09-24 |
EP2181992A4 (en) | 2011-09-14 |
CN101815713B (zh) | 2013-09-11 |
US20110009619A1 (en) | 2011-01-13 |
ES2529648T3 (es) | 2015-02-24 |
TW200916469A (en) | 2009-04-16 |
MX2010002098A (es) | 2010-03-30 |
AR068121A1 (es) | 2009-11-04 |
EP2559693A1 (en) | 2013-02-20 |
MY150507A (en) | 2014-01-30 |
JP5433418B2 (ja) | 2014-03-05 |
NZ583515A (en) | 2011-05-27 |
EP2181992A1 (en) | 2010-05-05 |
CA2694401A1 (en) | 2009-03-05 |
KR20100055456A (ko) | 2010-05-26 |
ZA201000474B (en) | 2011-05-25 |
EP2559693B1 (en) | 2014-11-26 |
PE20090674A1 (es) | 2009-06-19 |
CA2694401C (en) | 2012-12-04 |
WO2009028588A1 (ja) | 2009-03-05 |
AU2008292390A1 (en) | 2009-03-05 |
IL203778A (en) | 2013-11-28 |
CN101815713A (zh) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
UY30500A1 (es) | Compuestos de azabencimidazolilo | |
UY31189A1 (es) | Compuestos heterocíclicos | |
CO6331340A2 (es) | Pirrolo-pirimidinas y pirrolo piridinas | |
UY30282A1 (es) | Compuestos quimicos | |
SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
CL2012000001A1 (es) | Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros. | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
ECSP12011622A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
AR060675A1 (es) | Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos. | |
CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
CO6511222A2 (es) | Derivado de idenona y composición famacéutica que comprende el mismo | |
DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa | |
MA32841B1 (fr) | Composés de cycloundeca depsipeptides et leur utilisation comme médicament | |
DOP2010000317A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos |